Sector News

Tesaro, hit hard by recent trial woes, hunts buyers—again: report

November 20, 2018
Life sciences

Tesaro has reportedly tried to sell itself before, but to no avail. But its newly lowered share price may be sparking some new buyout interest.

The company has brought on financial advisers to help it weigh a sale after drawing attention from a potential suitor, Bloomberg reports, citing unnamed sources. Those advisers have started reaching out to other potential buyers, too.

A Tesaro spokesperson did not return a request for comment by press time.

It’s not the first time the Waltham, Massachusetts-based drugmaker, which markets PARP inhibitor Zejula, has weighed a sale. Last summer, the company put itself up for grabs and reportedly generated interest from then-M&A-starved Sanofi and another party, which was rumored to be Gilead.

This time, though, Tesaro’s recent stock-price woes may be fueling the fire. The company saw its shares hammered earlier this month when phase 1 data on an immuno-oncology combination underwhelmed investors. It’s also locked in an intensely competitive battle with PARP rivals Clovis Oncology and an AstraZeneca-Merck team, which market Rubraca and Lynparza, respectively.

And while both Sanofi and Gilead have since struck other sizable deals—Gilead nabbed CAR-T drug maker Kite for $11.9 billion, while Sanofi forked over $11.6 billion for hemophilia specialist Bioverativ—either could still find the prospect of swallowing Tesaro appealing, Wedbush Securities Inc. analyst David Nierengarten told Bloomberg.

“A company like Gilead that’s been expanding their oncology efforts would make a lot of sense, … but at these prices, it could be just about anyone with an oncology focus looking to get a product tucked into their portfolio,” he said, as quoted by the news service.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.